iwAL 2023 Session IV: Transplantation and immunotherapies in AML: improving patient outcomes
Oct 20, 2023
auto_awesome
Charles Craddock and David Sallman discuss transplantation and immunotherapies in AML, focusing on patient eligibility, challenges in CAR-T therapy, targeting pre-transplant minimal residual disease, and improving patient outcomes through DLI and gamma delta T cells. They also explore the design of a randomized study evaluating prophylactic DLI in high-risk AML patients.
CAR T-cell therapy in AML shows promise, but response rates and durability of responses need improvement, and innovative approaches like compound cars and personalized patient selection are being explored.
Measurable residual disease (MRD) is a prognostic indicator in AML, and targeting MRD-positive patients with novel therapies before transplant, especially less intensively treated and older patients, could improve outcomes and advance AML treatment.
Deep dives
Advancements in CAR T-cell development in AML
CAR T-cell therapy has shown promise in AML, with CD33, CD123, and CLL1 being the main targets in clinical trials. However, response rates have been low, and the durability of responses is a challenge. Optimism remains high, and researchers are exploring out-of-the-box approaches, such as compound cars with multiple antigens, to improve efficacy. The role of CAR T-cell therapy in patients with TP53 mutations is still uncertain, given the unique biology and immune microenvironment of these patients. While challenges remain, there is hope that CAR T-cell therapy can be optimized through early trials, personalized patient selection, and combination treatments.
The relevance of pre-transplant MRD in AML
Pre-transplant measurable residual disease (MRD) has been established as a prognostic indicator in AML. Standardized assays for detecting MRD, such as NPM1 and FLT3, have been developed. To leverage MRD in improving outcomes, researchers propose targeting MRD-positive patients with novel therapies before transplant, specifically focusing on less intensively treated patients and older patients who may benefit the most. By using a randomized approach, evaluating the impact of MRD-targeting interventions on transplant outcomes, and designing trials based on molecular profiles, researchers aim to develop new strategies to benefit patients and advance AML treatment.
Exploring cellular therapy post-transplant in AML
Cellular therapy, particularly donor lymphocyte infusion (DLI), has shown promise in AML patients post-transplant. While concerns about graft-versus-host disease (GVHD) exist, retrospective studies suggest that DLI can be effective in high-risk settings. To optimize DLI, dosing schedules and patient selection need further investigation. Additionally, novel approaches with specific T-cell subsets, such as gamma delta T cells, are being explored to reduce GVHD while enhancing the graft-versus-leukemia effect. Randomized studies, comparing expanded gamma delta T cell infusion with standard transplantation, could provide insights into the safety and efficacy of such interventions.
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, and Nelli Bejanyan, MD, Moffitt Cancer Center, Tampa, FL, discuss the most recent updates in transplantation and immunotherapies in AML, and further comment on how to improve outcomes for patients.